Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats.
Breast cancer is a major cause of mortality in Western countries and there is an urgent requirement for novel treatment strategies. The nonsteroidal sulphatase inhibitor 667 COUMATE inhibits hepatic steroid sulphatase and growth of oestrone sulphate stimulated tumours in the nitrosomethylurea-induced rat mammary model. Other compounds that contain an aryl sulphamate moiety, for example, oestrone-3-O-sulphamate, are sequestered into red blood cells (RBCs). The aims of this study were to determine the pharmacokinetics of 667 COUMATE and to investigate its sequestration into RBCs. We administered a single p.o. or i.v. dose (10 mg kg(-1)) of 667 COUMATE to rats and used a high-performance liquid chromatography method to measure the levels of the agent and its putative metabolites in plasma. 667 COUMATE had a bioavailability of 95% and could be detected in plasma for up to 8 h. Using two independent analytical methods, we demonstrated that 667 COUMATE is sequestered by RBCs both ex vivo and in vivo. Previous investigations have revealed that 667 COUMATE is rapidly degraded in plasma ex vivo. In this study, we demonstrate that 667 COUMATE is stabilised due to its sequestration into RBCs. In conclusion, the pharmacological efficacy and high oral bioavailability of 667 COUMATE may be partly a consequence of the ability of RBCs to both protect the agent from metabolic degradation and facilitate its transport to tissues. These data support the further clinical evaluation of this novel endocrine therapeutic agent.
Ireson
C R
CR
Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College, St Mary's Hospital, London W2 1NY, UK.
Chander
S K
SK
Purohit
A
A
Parish
D C
DC
Woo
L W L
LW
Potter
B V L
BV
Reed
M J
MJ
D000284:Administration, Oral; D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy*; D002851:Chromatography, High Pressure Liquid; D003374:Coumarins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004912:Erythrocytes / Q000737:chemistry*; D005260:Female; D007262:Infusions, Intravenous; D051381:Rats; D017208:Rats, Wistar; D013449:Sulfonamides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013451:Sulfonic Acids
D003374:Coumarins; D013449:Sulfonamides; D013451:Sulfonic Acids; C520511:irosustat